Yaping Shou, MD, Phd
Chief Executive Officer & Founder
A highly accomplished executive in the biotechnology and pharmaceutical sectors, bringing over 20 years of expertise in global oncology drug development. Holds both an MD and a PhD, blending clinical depth with strategic business leadership.
Education
MD: Zhejiang University Medical School
PhD: Drexel University and U of Pennsylvania
Post-Doctoral Fellow: National Cancer Institute
~100 journal/meeting publications and 6 patents
Seasoned Biopharma Executive
Trillium – Chief Medical Officer, resolved key challenges in early dev, driving company value to US$2.3b (acquired by Pfizer in 2021)
Takeda, Novartis, GSK - Executive Medical Director
10+ high-impact corporate awards on innovation & leadership
Strong track record of development success
20+ years leading global oncology clinical development, key contributor to regulatory approval of 5 targeted therapies
Pioneered biomarker-driven drug development
Signature science-based, data-driven approach to early development
Proven Business Leader
Fundraising (US$300M), investor relations, partnerships and alliance management, matrix team management, staffing & coaching
Budget and financial planning, corporate strategy
Venture Partner, Lilly Asia Ventures